Abbott Laboratories (ABT) climbed 1.82% during last trading as the stock added $0.73 to finish the day at $40.74 with about 8.73M shares changing hands, compared to its three month average trading volume of 9.46M. The $60.17B market cap company, which fluctuated between $40 and $40.81 during the day, currently situated 15.29% above its 52 week low of $36 and -10.46% away from its one year high of $46.38. The RSI of 43.01 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products, such as prepared infant and follow-on formulas. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. Abbott Laboratories was founded in 1888 and is headquartered in Abbott Park, Illinois.
The Mosaic Company (MOS) gained $0.85 to close the day at a new closing price of $24.69, a 3.57% increase in value from its previous closing price that moved the stock 15.6% above its 52 week low of $22.02. A total of 8.72M shares exchanged hands during the day compared with its three month average trading volume of 5.18M. The stock, which fluctuated between $23.59 and $24.85 during the day, currently situated -30.51% below its 52 week high. The stock is down by -2.49% in the past one month and down by -11.87% over the past three months. With a one year target estimate of $26.46 and RSI of 48.46, the stock still has upside potential, making it a hold for now.
The Mosaic Company, through its subsidiaries, produces and markets concentrated phosphate and potash crop nutrients primarily for the agricultural industry worldwide. The company operates through three segments: Phosphates, Potash, and International Distribution. It owns and operates mines, which produce concentrated phosphate crop nutrients, such as diammonium phosphate, monoammonium phosphate, and ammoniated phosphate products; and phosphate-based animal feed ingredients primarily under the Biofos and Nexfos brand names. The company also produces and sells potash for use in the manufacturing of mixed crop nutrients and animal feed ingredients, and for industrial use; and for use in the de-icing and as a water softener regenerant, as well as fluorosilicic acid for water fluoridation. In addition, it provides nitrogen-based crop nutrients and animal feed ingredients, and other ancillary services; and purchases and sells phosphates, potash, and nitrogen products. The company sells its products to wholesale distributors, retail chains, cooperatives, independent retailers, and national accounts. The Mosaic Company was founded in 2004 and is headquartered in Plymouth, Minnesota.
Boston Scientific Corporation (BSX) had a active trading with around 8.66M shares changing hands compared to its three month average trading volume of 7.77M. The stock traded between $22.67 and $23.03 before closing at the price of $23.01 with 0.61% change on the day. The Marlborough Massachusetts 01752 based company is currently trading 46.84% above its 52 week low of $15.67 and -7.18% below its 52 week high of $24.79. Both the RSI indicator and target price of 43.06 and $0 respectively, lead us to believe that it should be put on hold over the coming weeks.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.